Last week the website reported that the FDA approved a drug for claw hand – a painful condition that causes bent fingers. That was the news of the day. But ABCNews.com only briefly discussed claw hand before catapulting into a non-stop promotion of possible off-label use of the drug for Peyronie’s Disease – a condition in which the penis becomes painfully bent.
Look at how ABC framed this:
The headline is hype. It’s not a penis-straightening drug in the eyes of the FDA. It hasn’t been submitted for approval for that use.
And is that really an appropriate stock photo to use for this story?
But this story repeatedly promotes off-label use – something the drug company would get in trouble for if they had done it. What was the company’s role in this story? The story says the drug company “says that – as a safety precaution – it will do everything it can to discourage off-label use.” Yet, the drug company PR guy is quoted citing specific data on alleged effectiveness of the drug for Peyronie’s Disease. And the story ends, “If all goes well, (the drug company) says they hope to have the drug approved for Peyronie’s within two years.”
Hmmm. That makes the Peyronie’s benefits of the drug sound pretty good and pretty certain.
And let’s count the ways the story promoted off-label use with these excerpts:
1. “may serve as double-duty as a penis-straightener”
2. “The release of the drug this spring may lead to off-label use for Peyronie’s Disease.”
3. “urologists and patients will find frustrating” any company attempt to discourage off-label use.
4. “…there is great demand for any drug that could be shown to work (for Peyronie’s). Xiaflex may be that drug.”
5. “Peyronie’s sufferers may be ‘very motivated’ to take risks, especially since few other treatments work.”
6. “I’m sure there will be pressure [on urologists] to use it off-label…they have a cohort of patients waiting.” (urologist’s quote)
Only deep in the story – 665 words deep in a 795 word story – after all of this off-label promotion took place – was there specific discussion of the safety concerns that could burst this balloon. Excerpt:
“It is an invasive procedure with potential bad side effects [such as] impotence [or] penile fracture. I don’t think too many urologists will do off-label use until FDA approval for use in Peyronie’s Disease,” (a UCSF urologist) says.
Bruising, pain, and swelling at the injection site has also been reported in clinical trials of Xiaflex.
And even this came after a bold heading, “Relief Will Have To Wait.“
Why would ANYone report on a drug study that has yet to be completed, has not been subjected to peer review and is for an off label use?
Because ABC could put “penis-straightening” in the headline and draw more traffic?
Comments
Please note, comments are no longer published through this website. All previously made comments are still archived and available for viewing through select posts.
Comments are closed.
Our Comments Policy
But before leaving a comment, please review these notes about our policy.
You are responsible for any comments you leave on this site.
This site is primarily a forum for discussion about the quality (or lack thereof) in journalism or other media messages (advertising, marketing, public relations, medical journals, etc.) It is not intended to be a forum for definitive discussions about medicine or science.
We will delete comments that include personal attacks, unfounded allegations, unverified claims, product pitches, profanity or any from anyone who does not list a full name and a functioning email address. We will also end any thread of repetitive comments. We don”t give medical advice so we won”t respond to questions asking for it.
We don”t have sufficient staffing to contact each commenter who left such a message. If you have a question about why your comment was edited or removed, you can email us at feedback@healthnewsreview.org.
There has been a recent burst of attention to troubles with many comments left on science and science news/communication websites. Read “Online science comments: trolls, trash and treasure.”
The authors of the Retraction Watch comments policy urge commenters:
We”re also concerned about anonymous comments. We ask that all commenters leave their full name and provide an actual email address in case we feel we need to contact them. We may delete any comment left by someone who does not leave their name and a legitimate email address.
And, as noted, product pitches of any sort – pushing treatments, tests, products, procedures, physicians, medical centers, books, websites – are likely to be deleted. We don”t accept advertising on this site and are not going to give it away free.
The ability to leave comments expires after a certain period of time. So you may find that you’re unable to leave a comment on an article that is more than a few months old.
You might also like